Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice

Journal of Clinical Investigation

Volumn 122, Issue 1, 2012, Pages 178-191

  Panigrahy, Dipak ^a,b   Edin, Matthew L ^c   Lee, Craig R ^c,d   Huang, Sui ^e,f,m   Bielenberg, Diane R ^a   Butterfield, Catherine E ^a   Barnés, Carmen M ^a   Mammoto, Akiko ^a   Mammoto, Tadanori ^a   Luria, Ayala ^g   Benny, Ofra ^a   Chaponis, Deviney M ^a,b   Dudley, Andrew C ^a   Greene, Emily R ^a,b   Vergilio, Jo Anne ^b   Pietramaggiori, Giorgio ^h   Scherer Pietramaggiori, Sandra S ^h   Short, Sarah M ^a   Seth, Meetu ^a   Lih, Fred B ^c   Tomer, Kenneth B ^c   Yang, Jun ^g   Schwendener, Reto A ⁱ   Hammock, Bruce D ^g   Falck, John R ^j   Manthati, Vijaya L ^j   Ingber, Donald E ^a,k   Kaipainen, Arja ^l   D'Amore, Patricia A ^b   Kieran, Mark W ^a,b,m   Zeldin, Darryl C ^c,m   more..

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k HARVARD UNIVERSITY   (United States)

^l UNIVERSITY OF CALGARY   (Canada)

^m A214 ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; EPOXIDE HYDROLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DORMANCY; FIBROSARCOMA; GENETIC PARAMETERS; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MALE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL PARAMETERS; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84855453198     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58128     Document Type: Article

References (62)

1. Gronert K. Lipid autacoids in inflammation and injury responses: a matter of privilege. Mol Interv. 2008;8(1):28-35. (Pubitemid 351398450)
2. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 2007;49(3):590-596.
3. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med. 2008;18(1):20-25.
4. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794-805.
5. Shen HC. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat. 2010;20(7):941-956.
6. Munzenmaier DH, Harder DR. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol. 2000;278(4):H1163-H1167. (Pubitemid 30235492)
7. Pozzi A, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem. 2005;280(29):27138-27146. (Pubitemid 41040752)
8. Wang Y, et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther. 2005;314(2):522-532. (Pubitemid 41043832)
9. Panigrahy D, Kaipainen A, Greene ER, Huang S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 2010;29(4):723-735.
10. Jiang JG, et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005;65(11):4707-4715.
11. Jiang JG, et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 2007;67(14):6665-6674.
12. Jernstrom H, Bageman E, Rose C, Jonsson PE, Ingvar C. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer. 2009;101(11):1817-1823.
13. Zagorac D, Jakovcevic D, Gebremedhin D, Harder DR. Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. J Cereb Blood Flow Metab. 2008;28(8):1431-1439.
14. Node K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285(5431):1276-1279. (Pubitemid 29398616)
15. Lee CR, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010;24(10):3770-3781.
16. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275(51):40504-40510. (Pubitemid 32064687)
17. Seubert JM, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006;99(4):442-450. (Pubitemid 44253701)
18. Edin ML, et al. Endothelial expression of human cytochrome P450 epoxygenase CYPC8 increases susceptibility to ischemia-reperfusion injury in the isolated mouse heart. FASEB J. 2011;25(10):3436-3447.
19. Newman JW, Watanabe T, Hammock BD. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res. 2002;43(9):1563-1578.
20. Pettaway CA, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 1996;2(9):1627-1636. (Pubitemid 126447459)
21. Jeet V, Russell PJ, Khatri A. Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metastasis Rev. 2010;29(1):123-142.
22. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett. 2010;294(2):139-146.
23. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer. 2010;10(12):871-877.
24. Naumov GN, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98(5):316-325. (Pubitemid 43338211)
25. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1(2):149-153.
26. Almog N, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. 2006;20(7):947-949.
27. Naumov GN, MacDonald IC, Chambers AF, Groom AC. Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol. 2001;11(4):271-276. (Pubitemid 32799904)
28. Kaipainen A, et al. PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One. 2007;2(2):e260.
29. De Palma M, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14(4):299-311.
30. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95(3):272-281. (Pubitemid 44187587)
31. O'Reilly MS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-328. (Pubitemid 24324921)
32. Panigrahy D, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110(7):923-932.
33. Parhar RS, Lala PK. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2. J Exp Med. 1987;165(1):14-28. (Pubitemid 17223670)
34. Barbera-Guillem E, Smith I, Weiss L. Cancer-cell traffic in the liver. I. Growth kinetics of cancer cells after portal-vein delivery. Int J Cancer. 1992;52(6):974-977. (Pubitemid 23009518)
35. Price JE, Tarin D, Fidler IJ. Influence of organ microenvironment on pigmentation of a metastatic murine melanoma. Cancer Res. 1988;48(8):2258-2264.
36. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007;50(16):3825-3840. (Pubitemid 47292046)
37. Gauthier KM, et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002;90(9):1028-1036. (Pubitemid 34633870)
38. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB. 14,15-epoxyeicosa-5(Z)- enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension. 2003;42(4):555-561. (Pubitemid 37237353)
39. Deng Y, et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J. 2011;25(2):703-713.
40. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. Am J Physiol Heart Circ Physiol. 2009;296(5):H1352-H1363.
41. Motoki A, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008;295(5):H2128-H2134.
42. Webler AC, et al. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol. 2008;295(5):C1292-C1301. (Pubitemid 352790340)
43. Gross GJ, et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol. 2008;294(6):H2838-H2844.
44. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-364. (Pubitemid 26272076)
45. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-1027. (Pubitemid 46202320)
46. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549-560. (Pubitemid 43290332)
47. Kuo CJ, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 2001;98(8):4605-4610. (Pubitemid 32295023)
48. Streit M, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol. 1999;155(2):441-452. (Pubitemid 29370394)
49. Fukumura D, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94(6):715-725. (Pubitemid 28436004)
50. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168(2):639-648. (Pubitemid 43271161)
51. Enayetallah AE, French RA, Grant DF. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol. 2006;37(3-4):133-141.
52. Dudley AC, et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell. 2008;14(3):201-211.
53. Nakamura T, Kuwai T, Kim JS, Fan D, Kim SJ, Fidler IJ. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia. 2007;9(11):979-986. (Pubitemid 350086443)
54. Pietramaggiori G, Scherer SS, Alperovich M, Chen B, Orgill DP, Wagers AJ. Improved cutaneous healing in diabetic mice exposed to healthy peripheral circulation. J Invest Dermatol. 2009;129(9):2265-2274.
55. Folkman J. Angiogenesis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Textbook of Internal Medicine. New York, New York, USA: McGraw-Hill; 2001:517-530.
56. Harach HR, Fransilla KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systemic autopsy study. Cancer. 1985;56(3):531-538. (Pubitemid 15035581)
57. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer. 2010;46(7):1181-1188.
58. Schlaeger TM, et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997;94(7):3058-3063. (Pubitemid 27157263)
59. Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J, D'Amato RJ. Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods. 2009;342(1-2):78-81.
60. Panigrahy D, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A. 2008;105(3):985-990. (Pubitemid 351282068)
61. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol. 2005;168(4):643-653. (Pubitemid 40271029)
62. Lim YC, et al. Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. Am J Pathol. 2003;162(5):1591-1601.